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Statins are molecules of fungal origin, which inhibit the 
hydroxymethylglutaryl-CoA (HMG-CoA) reductase 
enzyme, a key step in the sterol biosysnthesis, rendering 
them powerful cholesterol lowering medications 
contributing to significant prevention of cardiovascular 
disease.1 Statins are characterized by differences in 
bioavailability, lipo/hydrophilicity, cytochrome P-450 
mediated metabolism and cellular transport mechanisms, 
differences that are reflected in their relative capacity in 
LDL-cholesterol lowering and possibly in parenchymal or 
muscular toxicities.2 Statin intolerance comprises, among 
others, musculoskeletal problems, such as statin-induced 
muscle and tendon disorders which are the most common 
cause of statin discontinuation.3-10
Musculoskeletal Problems
Statin therapy has long been associated with 
musculoskeletal (MS) problems in approximately 10% -
25% of patients treated in real-world clinical practice, but 
such problems have rarely been reported in controlled 
clinical trials,3,4 and their incidence has thus far been 
underestimated.5 Studies have concentrated on creatine 
kinase (CK) elevations to identify myopathy. However, 
many patients can have normal serum CK levels despite 
myalgia and persistent weakness and muscle biopsy -
proven myopathy. Discontinuation of statin and 
rechalllenge may be required to prove that it is statin-
related. Several risk factors may predispose patients to 
statin-related MS problems, including advanced age, 
family history of myopathy, statin dose, and interacting 
medications (e.g., azole antifungals, cimetidine, fibrates, 
macrolide antibiotics, protease inhibitors and 
cyclosporine) (Table 1).5,6,8
Musculoskeletal conditions, arthropathies, injuries, and 
pain appear to be more common among statin users than 
among similar nonusers. In a recent retrospective cohort 
study (N= 46,249; 13 626 statin users and 32 623 nonusers)
with propensity score matching (n=6967 statin users; n= 
6967 nonusers),7 the authors investigated whether statin 
use is associated with musculoskeletal conditions, 
including arthropathy and injury, in a military health care 
system. Statin-associated musculoskeletal adverse effects 
include a wide array of clinical presentations, including 
myalgias, muscle weakness, muscle cramps, 
rhabdomyolysis, autoimmune muscle disease, and 
tendinous diseases. Among matched pairs, statin users had 
a higher odds ratio (OR) for all musculoskeletal diseases 
(OR, 1.19), injury-related diseases (dislocation, sprain, 
strain) (1.13), and drug-associated musculoskeletal pain
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(1.09); the OR for arthropathies and related diseases was 
1.07 (P = 0.07). Secondary and sensitivity analyses 
revealed higher adjusted ORs for statin users in all 
outcome groups. The authors concluded that 
musculoskeletal conditions, arthropathies, injuries, and 
pain are more common among statin users than among 
similar nonusers.
A recent large cohort study reporting on 
discontinuation of statins in routine care settings indicated 
that statins were discontinued at least temporarily for 
57,292 out of 107,835 patients.9 Statin-related events were 
documented for 18,778 (17.4%) patients, - a substantially 
higher rate than the 5-10% rate usually described in 
randomized placebo-controlled clinical trials. Similar to 
both clinical trials and observational studies, musculo-
skeletal symptoms predominated - accounting for 40% of 
statin-related events. However, overt rhabdomyolysis was 
found in only 0.006% of the study patients, also consistent 
with previous reports that statin-induced severe myopathy 
is a rare event. In this study, the majority (>90%) of 
patients who were rechallenged with a statin after a statin-
related event, were finally able to tolerate one. The authors 
concluded that statin-related events are commonly 
reported and often lead to the discontinuation of statins; 
nearly 1 in 5 patients in this cohort stopped all statins for 
at least 12 months. However, most patients who are 
rechallenged can tolerate statins long-term. This suggests 
that many of the statin-related events may have other 
etiologies, are tolerable or may be specific to individual 
statins rather than the entire drug class. 
Table 1. Risk Factors for Developing Statin-Related 
Musculoskeletal Problems
Age > 75-80 years old Drugs
Female gender Fibrates
Low BMI, frail Cyclosporine
History (or FH) of muscle 
symptoms / dLVHDVHĹ&.
Protease inhibitors
History (or FH) of statin 
intolerance
Antibiotics: Macrolides / Da-
ptomycin/ Antifungals (Azole)
/ Rifampin/ Fusidic acid
Renal / Liver disease Ranolazine
Diabetes Amiodarone/Dronedarone
Vitamin D deficiency Verapamil/Diltiazem
Hypothyroidism Cocaine
High-dose statin Danazol
Type of statin Warfarin
Physical exercise Cimetidine
Major surgery Nefazodone
Genetic polymorphisms Colchicine
Grapefruit juice Nicotinic acid
Alcohol Dasatinib
BMI = body mass index; CK = creatine kinase; FH = family history
Myopathies
The above and other recent papers on statin-induced 
myopathy have lately spawned an intense discussion and 
controversy regarding the results of randomized controlled 
trials reporting a much lower incidence of such adverse 
effects.7,9,11-14 A recent review and meta-analysis of 
observational studies has confirmed the increased 
incidence of statin-related myopathy with an odds ratio of 
2.63,15 further fueling the heated discussion emanating 
from the recent guidelines recommending an expansion of 
the population base to receive statins. The authors of this 
review indicate that their analysis giving higher estimates 
than randomized controlled trials for myopathy may reflect 
differences in the diagnostic criteria used and the 
populations studied. They emphasize that myopathy is 
more likely to occur with higher doses of statins and 
randomized controlled trials have excluded situations that 
raise statin blood levels, including advanced age, frailty, 
deterioration of renal function and the presence of 
interacting drugs. 
The spectrum of statin-related myopathies ranges from 
common, albeit clinically benign, myalgia without CK 
elevation to typical myositis with CK elevation to rare but 
life-threatening rhabdomyolysis. It is estimated by 
observational studies that 10 - 15% of statin users develop 
statin-related muscle side effects. Fortunately, the more 
severe form of rhabdomyolysis remains rare.3-9
The mechanisms of statin-related myopathies have not 
been clearly elucidated. However, strong evidence has 
emerged from observational and clinical studies that 
skeletal muscle toxicity is a dose-dependent feature 
associated with all statins, with some (lipophilic) statins 
being more toxic than others (hydrophilic statins), 
primarily related to the reduced availability of metabolites 
produced by the mevalonate pathway rather than 
intracellular cholesterol lowering per se which include 
alteration in isoprenoids synthesis.16 In general, there is a 
complex interplay between drug–environment and drug–
drug interaction in the context of different genetic settings 
contributing to statin-induced skeletal muscle toxicity. Of 
note, an important metabolite derived from cholesterol is 
vitamin D, produced when 7-dehydrocholesterol is 
converted by ultraviolet B light to active vitamin D3 in the 
skin. Importantly, vitamin D deficiency can cause muscle 
weakness, generalized muscle pain, and levels of vitamin 
D <30 nmol/L are associated with decreased muscle 
strength. Indeed, a cross-sectional study showed that low 
levels of vitamin D were associated with increased statin-
induced skeletal muscle complaints 17 suggesting a 
reversible interaction between vitamin D deficiency and 
statins on skeletal muscle. However, the role of vitamin D 
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on induction or protection from muscle toxicity during 
statin therapy remains unclear.
Options for managing statin myopathies include lower 
dose of statin, statin switching, particularly to fluvastatin 
or low-dose rosuvastatin; nondaily dosing regimens;18,19
nonstatin alternatives, such as ezetimibe and bile acid-
binding resins (colesevelam); and coenzyme Q10 
supplementation. However, the evidence supporting such 
strategies remains scanty. Re-initiation of statins in a 
patient who has exhibited statin-related MS problems 
should be individualized and caution should be 
exercised.20,21 If the diagnosis of statin-induced myopathy 
was correct and there were no modifiable risk factors, the 
likelihood is high that the problem will recur upon 
rechallenge with same statin at the same dose. A modified 
approach by switching to another statin and using a low 
dose may reduce the risk of recurrence. 
Statin-related myopathies will probably become more 
prevalent in the future with greater numbers of persons 
being placed on statin therapy, as recommended by the 
recent ACC/AHA guidelines,1,8 despite the controversy 
they have invoked, and thus there is need for further 
research to better identify patients at risk for statin 
myopathy and to evaluate management strategies for 
statin-related myopathy. 
Tendinopathies
In addition to muscle toxicity, statins have also been 
implicated in drug-induced tendon toxicity, which is rare 
but often underestimated. 7,22 Statins are among the four 
main drug classes which have been incriminated in 
tendinopathies, 23 with quinolones and long-term 
glucocorticoids being the most widely known, but statins 
and aromatase inhibitors can also induce tendon damage. 
The pathophysiological mechanisms underlying drug-
induced tendinopathies remain unknown. Identified risk 
factors may include age >60 years, pre-existing 
tendinopathy, and drug combinations potentiating these 
toxic effects. Mean time to symptom onset varies among 
the drug classes and reaches several months for statins. The 
most frequent sites of involvement are the lower limb 
tendons, most commonly the Achilles tendon. The most 
dramatic clinical manifestation of tendininous disorders is 
tendon rupture.10,24,25 Tendon rupture usually occurs in 
injured tendons. Physiological repair of an injured tendon 
requires degradation and remodeling of the extracellular 
matrix through matrix metalloproteinases (MMPs). The 
authors of a statin-related spontaneous biceps tendon 
rupture have put forth the hypothesis that statins may 
increase the risk of tendon rupture by inhibiting MMP 
activity.24
French investigators have analyzed 96 reports of tendon 
disorders attributed to statins.10 Patients had tendinitis 
(66%) and tendon rupture (34%). The Achilles tendon was 
most often affected. This adverse effect mainly occurred 
during the first year of treatment and appeared to be more 
frequent in patients with diabetes, hyperuricemia or a 
history of tendon disorders, and in persons engaging in 
strenuous sports. Reinitiation of statin in a few cases 
results in recurrence of tendinopathy in all cases. In 
practice, tendinopathy appears to be a rare adverse effect 
of statins, but patients should be closely monitored during 
the first year of treatment, especially when they have 
associated risk factors. 
Autoimmune Necrotic Myositis
Persistent weakness after statin withdrawal has also 
been reported, attributed to severe form of autoimmune 
necrotic myositis triggered by statins; successful treatment 
has been applied with use of intravenous 
immunoglobulins, combined with steroids and 
metothrexate.26 Detection of serum antibodies to the target 
enzyme of statins (3-hydroksy-3-methylglutaryl-
coenzyme A reductase) has been reported in cases of 
inflammatory and necrotizing myopathies.27,28 Even 
myasthenia gravis has been associated with intake of 
statins. 29
Statin Muscle Safety Task Force
Recently, a Statin Muscle Safety Task Force, the 
National Lipid Association’s Muscle Safety Expert Panel, 
was convened and charged with the duty of examining the 
definitions for statin-related MS problems, development of 
a clinical index to assess myalgia, and the use of diagnostic 
neuromuscular studies to investigate muscle adverse 
events.30 The Panel developed an algorithm for the 
evaluation and treatment of patients who may be intolerant 
to statins as the result of adverse muscle events. The Panel 
has attempted to answer this year’s questions. The answer 
was affirmative to the first question of whether statin-
associated myalgia could be reliably differentiated from 
myalgia associated with a placebo, based on the results of 
the STOMP trial.31 For this purpose, the suggested 
standard definition of statin-related myalgia includes: 
ƔQHZ-onset or increased symptoms of myalgia (muscle 
aches, stiffness, cramping, soreness, and tenderness) that 
are unassociated with recent exercise;
ƔV\PSWRPVWKDWSHUVLVWIRUDWOHDVWZHHNV
ƔV\PSWRPVWKDW UHVROYHZLWKLQZHHNVRIVWRSSLQJ WKH
study drug; and
Ɣ V\PSWRPV WKDW UHFXUZLWKLQ ZHHNV RI UHVWDUWLQJ WKH
medication.
The Panel admitted that there have been no validated 
scales to diagnose statin-associated myalgia. Nevertheless, 
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they propose a quantitative myalgia score that is largely 
based on the findings from the STOMP trial.31 This statin 
myalgia clinical index score rates the symptoms as 
probable, possible, or unlikely related to statin. Statin-
associated muscle pain usually affects the lower limbs, as 
reported in the PRIMO study,3 and are likely to occur 
within the first month of therapy. 
The Panel indicated that statins are less tolerated in
physically active individuals, as the statin-associated 
muscle complaints are proportional to the acute and 
chronic physical activity.30 The data suggest that statin 
therapy may produce a greater incidence of muscle-related 
side effects in chronically physically active individuals and 
may also exacerbate skeletal muscle damage and CK 
release during acute exercise. The Panel also provided 
diagnostic criteria for statin-induced myopathy, which 
include proximal weakness detected on physical 
examination and standardized muscle testing and finally 
confirmed by electromyography plus/minus muscle 
biopsy. For the timing of muscle biopsy, the Panel 
recommended to start with an electromyogram (EMG), 
and to proceed to biopsy in those individuals with 
fibrillations and/or positive sharp waves in the affected 
muscles to assist in correctly diagnosing the type of muscle 
disorder that is responsible for the CK elevation, after a 
thorough neurological examination has excluded certain 
neuropathies and radiculopathies. 
The Panel also agreed that according with retrospective 
data derived from registries, most (~90%) patients who are 
intolerant to one statin because of myalgia can generally 
tolerate a different statin.30 Although some propose a statin 
that is independent of cytochrome P450 3A4 metabolism 
such as pravastatin, rosuvastatin, fluvastatin, or pitava-
statin, there have been no randomized studies confirming 
this recommendation. Some have suggested that lipophilic 
statins (simvastatin/lovastatin) are more likely to produce 
muscular effects as opposed to the more hydrophilic statins 
(pravastatin, rosuvastatin, and fluvastatin), but again this 
needs to be put to test by appropriately designed studies. 
Others have related the muscle toxicity to specific drug 
potency, with relative adverse event risks being higher 
with higher potency statins.32
For statin-intolerant patients, the Panel recommends 
alternate-day or non-daily dosing with statins of long half-
life (rosuvastatin and atorvastatin),19 although these dosing 
regimens have not been studied in terms of their 
effectiveness in reducing cardiovascular events. 18,30
Finally, when all else has failed, nonstatin LDL-C-
lowering therapies (ezetimibe, colesevelam) may be 
employed or added to low-dose statin therapy. 
Supplemental use of vitamin D or coenzyme Q10 has also 
been suggested but remains to be proven effective. 
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REVIEW
Beta-Blockers in Post-MI Patients: Need to Re-
consider?
Prokopis Papadimitriou, MD, Antonis S. Manolis, MD
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Athens, Greece 
Abstract
International clinical practice guidelines recommend 
early introduction and continued treatment with beta-
blockers for all patients without contraindications after 
STEMI. Although there seemed to be little question that 
patients with STEMI, regardless of revascularization 
strategy, derive substantial benefits from both long- and 
short-term beta-blockade, there has been a paucity of high 
quality evidence supporting this notion and the majority of 
data predate modern reperfusion therapy and current 
medical management strategies with statins and 
antiplatelet agents. Recently published data question this 
“one-size-fits-all” approach, showing that the use of beta-
blockers increased the risk of heart failure and cardiogenic 
shock with no mortality benefit.
Key Words: acute myocardial infarction; beta-blockers;
heart failure; cardiogenic shock
List of Abbreviations
AMI = acute myocardial infarction; EF = ejection fraction; ICD 
= implantable cardioverter defibrillator; HF = heart failure; LV 
= left ventric-le(-ular); MACE = major cardiovascular events; 
MI = myocardial infarction; NSTEMI = non-ST-elevation 
myocardial infarction; PCI = percutaneous coronary 
intervention; RAAS = renin-angiotensin aldosterone system; 
STEMI = ST-elevation myocardial infarction; VF = ventricular 
fibrillation
Introduction
Beta adrenergic receptor blockers have long been 
recommended for the treatment of all stages of ischemic 
heart disease, with the exception of Prinzmetal's 
vasospastic variant angina. Beta-Blockade is still regarded 
as standard therapy for effort angina, mixed effort and rest 
angina, and unstable angina. International clinical practice 
guidelines recommend beta-blocker therapy, both short-
and long-term, to all acute coronary syndrome patients 
without contraindications, regardless of the 
revascularization strategy. However, much of the data to 
support their use predates reperfusion and contemporary 
medical therapy, while controversy also exists over the 
optimum timing of therapy initiation and discontinuation. 
Mechanisms of beta-blockers action
Potentially beneficial effects of beta-blockers in 
patients with acute myocardial infarction (MI) include: 1,2
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